Literature DB >> 29941531

FDA approves licensing of erenumab-aooe to prevent migraine.

Kate Traynor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29941531     DOI: 10.2146/news180044

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  7 in total

Review 1.  Structural Basis for Allosteric Modulation of Class B G Protein-Coupled Receptors.

Authors:  Denise Wootten; Laurence J Miller
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-08-27       Impact factor: 13.820

2.  Drosophila CaV2 channels harboring human migraine mutations cause synapse hyperexcitability that can be suppressed by inhibition of a Ca2+ store release pathway.

Authors:  Douglas J Brusich; Ashlyn M Spring; Thomas D James; Catherine J Yeates; Timothy H Helms; C Andrew Frank
Journal:  PLoS Genet       Date:  2018-08-06       Impact factor: 5.917

Review 3.  Pathological Mechanisms and Therapeutic Targets for Trigeminal Neuropathic Pain.

Authors:  Pawan Bista; Wendy L Imlach
Journal:  Medicines (Basel)       Date:  2019-08-22

4.  Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review.

Authors:  Tianwei She; Yaoyao Chen; Taichun Tang; Min Chen; Hui Zheng
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 5.  Anti-migraine agents from an immunological point of view.

Authors:  Bakri M Assas
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

Review 6.  The Role of Neuro-Immune Interactions in Chronic Pain: Implications for Clinical Practice.

Authors:  Po-Yi Paul Su; Lingyi Zhang; Liangliang He; Na Zhao; Zhonghui Guan
Journal:  J Pain Res       Date:  2022-08-04       Impact factor: 2.832

7.  Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis.

Authors:  Yanbo Yang; Mingjia Chen; Da Wu; Yue Sun; Fan Jiang; Zhouqing Chen; Zhong Wang
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.